奥赛康：子公司与阿诺医药达成许可引进协议

Core Viewpoint - Aosaikang Pharmaceutical has entered into a licensing agreement with Hangzhou Anuo Biopharmaceutical Technology, acquiring exclusive rights for the development, production, and commercialization of the innovative drug AN9025, a pan-RAS inhibitor targeting RAS mutation-related solid tumors [1][2] Group 1: Financial Terms of the Agreement - Aosaikang Pharmaceutical will pay a non-refundable upfront fee of 35 million RMB within 10 working days after the agreement takes effect [1] - Total milestone payments related to product development, registration, and market launch will not exceed 470 million RMB [1] - Additional payments related to sales milestones will not exceed 1.128 billion RMB [1] Group 2: Product Details and Clinical Development - AN9025 is a novel oral pan-RAS inhibitor that effectively targets KRAS, NRAS, and HRAS mutations by forming a ternary complex with activated RAS-GTP and molecular chaperone [1] - The drug is intended for the treatment of RAS mutation-related solid tumors and has received clinical trial approval from the FDA in the United States [1] Group 3: Strategic Implications for Aosaikang - The introduction of AN9025 enhances Aosaikang's pipeline in oncology, particularly in lung cancer, colorectal cancer, and pancreatic cancer, reinforcing its competitive position in these therapeutic areas [2] - The collaboration is expected to create synergies with the company's existing clinical and commercialization resources, positively impacting its strategic layout in the oncology sector [2]